Ogni cultura porta con sé delle storie e le narra attraverso le maschere. Io faccio lo psichiatra, ma nella mia vita mi sono occupato di di antropologia e sono stato a contatto con diverse culture. E queste maschere vengono utilizzate chi per spaventare oppure anche per portare dei messaggi, per curare oppure per parlare con il mondo degli spiriti.E questo l'esempio di questa maschera qui. Questa è una maschera del mondo voodo. Siamo nel Benen, Africa occidentale e questa è una maschera che viene impersonat ...

Alto Neuroscience (ANRO) Update / Briefing June 03, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Alto Neuroscience Investor Conference Call to discuss the company's acquisition of a novel dopamine agonist combination product candidate. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I will now turn the call over to Amit Edkin, Founder ...

Summary of Lipocene's Conference Call Company Overview - **Company Name**: Lipocene - **Ticker**: LPCN - **Market Cap**: Approximately $20 million - **Focus**: Biopharmaceutical company developing treatments for postpartum depression and obesity management [1][2] Core Products and Pipeline LPCN 1150 (Postpartum Depression Treatment) - **Mechanism**: Brexanolone (allopregnanolone), a bioidentical hormone that stabilizes mood, is a GABA positive allosteric modulator [24][25] - **Market Potential**: Approximately 250,000 mothers suffer from postpartum depression, with 60,000 to 80,000 seeking intervention [30][31] - **Clinical Development**: - Phase III study initiated, outpatient design, 48-hour treatment duration, targeting 80 patients [25][27] - Expected ANDA filing in about a year, with low clinical risk due to established efficacy of the molecule [26][27] - **Market Share Potential**: Estimated 30% to 50% market share, with market size projected between $500 million to $1 billion in the US [31][32] LPCN 2401 (Obesity Management) - **Target Population**: GLP-1 users, with nearly 30 million Americans expected to use GLP-1s [5][6] - **Mechanism**: A bioidentical myostatin inhibitor that works on fat, muscle, and bone, showing positive Phase II results [7][12] - **Clinical Development**: - Upcoming Phase II proof of concept study as an adjunct to GLP-1, with first patient dosing expected in Q3 of the current year [13][18] - Focus on weight loss and fat loss, with a goal to maintain or improve GLP-1 related weight loss [9][10] - **Market Opportunity**: Addresses unmet needs in quality weight loss and fat loss, particularly for patients concerned about weight rebound after stopping GLP-1 [12][15] Financial Overview - **Cash Management**: - Current spending is approximately $3 million per quarter, with cash runway expected for at least 12 months [33] - Focused and frugal spending strategy to support ongoing studies [33] Key Takeaways - **Investor Interest**: Both LPCN 1150 and LPCN 2401 are seen as valuable assets, with significant market potential in their respective fields [4][5] - **Regulatory Perspective**: Positive regulatory feedback for LPCN 1150, allowing for outpatient studies, which is favorable for product labeling [27] - **Partnership Opportunities**: The company is open to partnerships for LPCN 2401 post-proof of concept [19][20] Additional Insights - **Market Trends**: Increasing diagnosis rates for postpartum depression and obesity management create a favorable environment for Lipocene's products [31][21] - **Clinical Efficacy**: Previous studies indicate strong efficacy for both LPCN 1150 and LPCN 2401, with a focus on quality weight loss and maintaining lean mass [15][16][17]

- BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours after dosing A single dose of BPL-003 induced rapid and long-lasting antidepressant effects, with a mean MADRS (Montgomery-Asberg Depression Rating Scale) reduction of 18 points from baseline observed the day after dosing, a mean MADRS reduction of 19 points from baseline observed one month after dosing, and a mean MADRS reduction of 18 points from baseline observed three months after dosing. T ...

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, Uni ...

COMPASS Pathways (CMPS) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Steve Schultz - Senior Vice President, Investor RelationsKabir Nath - Chief Executive OfficerTeri Loxam - CFO, Principal Financial Officer & Principal Accounting OfficerGuy Goodwin - Chief Medical OfficerPaul Matteis - Managing Director, Head of Therapeutics ResearchCharles Duncan - Managing DirectorSteve Levine - Chief Patient OfficerSumant Kulkarni - Managing DirectorPatrick Trucchio - Managing Director Conference ...

Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $315.3 million as of March 31, 2025 DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depressio ...

LivaNova (LIVN) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Briana Gotlin - VP-IRVladimir Makatsaria - CEOAhmet Tezel - Chief Innovation OfficerAlex Shvartsburg - Chief Financial OfficerRick Wise - Managing Director - Medical Technology & SuppliesDavid Roman - Managing DirectorStephanie Bolton - President of Global Epilepsy Conference Call Participants Adam Maeder - Senior Research AnalystMichael Sarcone - AnalystMike Matson - Senior Equity Research AnalystDavid Rescott - Senior Rese ...

Core Viewpoint - NRx Pharmaceuticals has filed a patent application for NRX-100, a preservative-free intravenous ketamine formulation aimed at treating suicidal depression, which could provide exclusivity until 2045 if granted [1][2][8] Group 1: Product Development - NRX-100 is specifically designed without benzethonium chloride or other preservatives, addressing safety concerns associated with these compounds [2][8] - The formulation demonstrates room temperature shelf stability without toxic excipients, potentially allowing it to be listed in the FDA Orange Book [2][8] - The company has initiated a New Drug Application (NDA) filing for NRX-100 based on clinical trial results and data from French health authorities [5] Group 2: Regulatory and Market Strategy - NRx Pharmaceuticals has received Fast Track Designation from the FDA for NRX-100, facilitating its development for patients with acute suicidality [5] - The company is committed to delivering safer treatments for suicidal depression, reflecting a focus on patient well-being [3] - The recent FDA fee waiver is expected to aid in the timely completion of the NDA submission [3] Group 3: Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain [4] - The company is also developing NRX-101, which has been designated as an investigational Breakthrough Therapy by the FDA [4]

Phase 2b/3 Alzheimer’s trial enrolment expected to reach 100 this quarter, triggering an interim analysis 6 months laterSYDNEY, April 30, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that its Alzheimer’s disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by the end of this quarter. That milestone will trigger an interim analysis of available trial data by an independent Data Monitoring Committee approximately 6 months later. Final results for the fu ...